Mobile

A twelve-week, randomized, double-blind, multi-center,parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chroni...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-010208-27

A twelve-week, randomized, double-blind, multi-center,parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate the efficacy of LCZ696 in patients with chronic heart failure with preserved ejection fraction (HF-PEF) by testing the hypothesis that the reduction in NT-proBNP from baseline to study end with LCZ696 is greater than that with valsartan after 12-weeks of treatment

Critère d'inclusion

  • Chronic Heart Failure

Liens